US IVD (In Vitro Diagnostic) growth set to continue despite cost constraints
This article was originally published in Clinica
US demand for in vitro diagnostic (IVD) reagents and instrumentation will continue to grow at 6% a year to reach $10.5 billion by 2003. Cost-containment pressures will continue to force prices down and constrain demand, but this will be more than offset by the growth of the point-of-care and home testing markets. These are the conclusions of the Freedonia Group, a US industrial market research company.
You may also be interested in...
The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.